Trial · NCT06660498
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of treatment, measured as the time from ART cessation until meeting ART restart criteria. | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Primary | Safety of treatment, measured by the number of treatment-emergent adverse events (AEs) of grade 3 or higher that are probably or definitely related to the study treatment. | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | Safety, defined as all other treatment-emerging adverse events (AEs) | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | AEs are graded according to severity and assessed as either not related or possibly, probably or definitely related to study treatment. |
| Secondary | Rebound viral kinetics during the ATI, including plasma HIV-1 RNA copies/mL doubling times | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The proportion of participants maintaining HIV-1 RNA levels below 1,000 copies/mL at the end of the ATI. | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The proportion of participants who have not met ART restart criteria at the end of the ATI. | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The frequency of peripheral blood CD4+ T cells containing total and intact HIV-DNA while on suppressive ART | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | HIV-specific CD4+ responses | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | HIV-specific CD8+ T cell responses | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The proportion of cells containing constitutive and inducible MS HIV-RNA | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The level of CA-US HIV RNA in peripheral blood CD4+ T cells | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | Numbers of B cells, total lymphocytes, CD8+ T cells and CD4+ T cells including memory subsets | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | Proportions of B cells, total lymphocytes, CD8+ T cells and CD4+ T cells including memory subsets | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06660498/registered